Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study
NCT04768504 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2
Last updated 2024-11-25
Summary
This is a single-arm pilot study evaluating the efficacy and safety of tofacitinib in cancer patients with immune-related colitis from immune checkpoint inhibitor (ICI) therapy.
Conditions
- Immune-Mediated Colitis
Interventions
- DRUG
-
Tofacitinib 10 mg
Tofacitinib 10 mg PO BID for 30 days
Sponsors & Collaborators
-
Khashayar Esfahani
lead OTHER
Principal Investigators
-
Khashayar Esfahani, MD · Jewish General Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-22
- Primary Completion
- 2024-01-17
- Completion
- 2024-01-17
Countries
- Canada
Study Locations
More Related Trials
-
Tofacitinib For Treatment Of Chronic Pouchitis
NCT04580277 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
NCT04624230 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms
NCT03601611 ·Status: COMPLETED ·Phase: NA
-
Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
NCT03765450 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801 ·Status: RECRUITING ·Phase: PHASE3
-
Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease
NCT05910528 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855 ·Status: RECRUITING ·Phase: PHASE3
-
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
NCT01465763 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
NCT06807593 ·Status: RECRUITING ·Phase: PHASE2
-
Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes.
NCT05069259 ·Status: TERMINATED
-
Tofacitinib Registry of Patients With Ulcerative Colitis in Germany
NCT04032756 ·Status: TERMINATED
-
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891 ·Status: RECRUITING ·Phase: PHASE3
-
This Study is to Describe and Evaluate Patients in Finland Treated With Tofacitinib for the Treatment of Ulcerative Colitis Using Real World Data.
NCT05082428 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336 ·Status: RECRUITING ·Phase: PHASE2
-
Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets
NCT03090139 ·Status: COMPLETED
-
An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data From the United Registries for Clinical Assessment and Research (UR-CARE) in the European Union (EU)
NCT06469424 ·Status: RECRUITING
-
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878 ·Status: RECRUITING ·Phase: PHASE3
-
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease
NCT00269841 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
NCT03107793 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease
NCT00808262 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
NCT05313620 ·Status: RECRUITING ·Phase: PHASE4
-
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
NCT01635621 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
NCT01458951 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
NCT07298421 ·Status: RECRUITING ·Phase: PHASE3